The current clinical pipeline for new antibiotics fails to address the significant threat posed by drug-resistant Gram-negative bacteria which have been identified by the World Health Organization (WHO) as a global health priority. As companies continue to leave the field of antibiotic development, many researchers have also retired or re-focused their activities on other areas. The shifts away from the field risk the loss of invaluable experience and knowledge that is crucial for the discovery, research and development of urgently needed antimicrobial treatments.

The Global Antibiotic R&D Partnership (GARDP) launched REVIVE in 2018 to ensure knowledge is retained, and the antimicrobial R&D community is supported online to connect, share, and acquire information. Through our scientific affairs & REVIVE activities, we are helping advance the development of new treatments by freely sharing the knowledge and skills of antimicrobial R&D experts with the global research community.

REVIVE aims to improve, accelerate, and streamline antimicrobial drug discovery and R&D by directly connecting researchers with established and retired antimicrobial researchers and developers, and by facilitating learning and knowledge exchange.

**FACILITATING LEARNING**
REVIVE has a strong educational focus with its greatest achievement to date being its open access webinars (that include interactive Q&A sessions), which are the most developed and appreciated feature of the programme. Webinars are led by internationally renowned experts and enable users to take part anytime, anywhere and free of charge. With over 9000 participants from more than 120 countries, the value of these webinars is very high. As of May 2022, we streamed 49 webinars with an average of 185 participants per session.

Alongside the webinars, GARDP’s scientific affairs team develops content and co-organizes the Antimicrobial Chemotherapy Conference, and symposia, bootcamps and workshops at leading international scientific conferences in collaboration with other organizations in the field. These include the British Society for Antimicrobial Chemotherapy, CARB-X, JPIAMR, REPAIR Impact Fund and the Wellcome Trust. Fulfilling its aim for inclusiveness and accessibility, GARDP makes recordings of these conference sessions available freely on the REVIVE website – revive.gardp.org.

**CONNECTING PEOPLE**
REVIVE provides all those in the antimicrobial field, from academia, start-ups, biotech and large companies, with access to scientific advice from experienced drug developers. The REVIVE expert network of over 140 specialists from 23 countries is continuously growing with the aim of representing an international group of senior scientific and medical professionals.

**SHARING KNOWLEDGE**
Through its Antimicrobial Viewpoints, GARDP aims to share knowledge and stimulate discussions on highly relevant topics in the antimicrobial resistance (AMR) space. Viewpoints are articles written by high-profile international AMR experts who share insights on drug discovery, R&D, infectious diseases and clinical microbiology as well as economics, policy and drug development. The authors share their knowledge and opinions about the current status and the future challenges in this field. As of May 2022, 45 articles were published on the REVIVE website.

The Antimicrobial Encyclopaedia was launched and defines over 210 terms used in the field with some including videos by leading experts. This is part of a broader resources section, which also includes a library with external sources.
5 BY 25
GARDP is calling on the world to support the delivery of five new treatments by 2025 to tackle the drug-resistant infections that pose the greatest threat to global health and economic security. We are seeking €500 million to develop these treatments and ensure their responsible use and sustainable access.

GARDP’s external scientific affairs & REVIVE activities are helping us achieve 5 BY 25. By facilitating learning, connecting the antimicrobial R&D community across sectors, and ensuring that valuable expert knowledge is shared globally, this platform is helping to accelerate the research and development of new life-saving antibiotics.

A GLOBAL PARTNERSHIP
REVIVE has partnered with leading experts from across the world to share their critical knowledge and experience with users.

There are currently over 140 world-class experts from 23 countries supporting REVIVE.